Biotechnology company Immunome Inc (NASDAQ: IMNM) announced on Monday that it has dosed the first patient in its Phase 1 trial of IM-1021, a ROR1-targeted antibody-drug conjugate (ADC).

This open-label, multicentre study aims to evaluate safety, tolerability, pharmacokinetics and preliminary anti-tumour activity in patients with advanced B-cell lymphomas and solid tumours.

IM-1021 incorporates Immunome's proprietary TOP1 inhibitor, HC74, designed to enhance targeted cancer therapy.

The company continues to advance its oncology pipeline, which includes varegacestat, a gamma secretase inhibitor in Phase 3 trials for desmoid tumours, and IM-3050, a FAP-targeted radioligand expected to enter clinical trials in 2025.